3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with butaclamol in 3 studies
| Studies (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Trials (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Recent Studies (post-2010) (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Studies (butaclamol) | Trials (butaclamol) | Recent Studies (post-2010) (butaclamol) |
|---|---|---|---|---|---|
| 330 | 40 | 33 | 33 | 0 | 8 |
| Protein | Taxonomy | 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide (IC50) | butaclamol (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | 0.0123 | |
| D | Rattus norvegicus (Norway rat) | 0.002 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.002 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.05 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.05 | |
| D(1B) dopamine receptor | Homo sapiens (human) | 0.05 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.002 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.002 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0139 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0053 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0525 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Billings, J; Kung, HF; Kung, MP; Murphy, RA | 1 |
| Guo, YZ; Kasliwal, R; Kung, HF; Kung, MP; Mach, RH; Pan, SG | 1 |
| Billings, J; Chumpradit, S; Kung, HF; Kung, MP; Mach, R | 1 |
3 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and butaclamol
| Article | Year |
|---|---|
Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents.
Topics: Animals; Benzofurans; Binding, Competitive; Chemical Phenomena; Chemistry; Corpus Striatum; Iodine Radioisotopes; Isotope Labeling; Male; Molecular Structure; Pyrrolidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Tissue Distribution | 1990 |
Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide.
Topics: Animals; Benzamides; Chemical Phenomena; Chemistry; Corpus Striatum; In Vitro Techniques; Iodine Radioisotopes; Male; Pyrrolidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Stereoisomerism; Structure-Activity Relationship | 1988 |
Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT.
Topics: Animals; Benzamides; Dopamine Agents; Dopamine D2 Receptor Antagonists; Fluorine Radioisotopes; Iodine Radioisotopes; Macaca fascicularis; Male; Pyrrolidines; Radionuclide Imaging; Rats; Rats, Sprague-Dawley; Tissue Distribution; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1993 |